Nelson Heidi D, O'Meara Ellen S, Kerlikowske Karla, Balch Steven, Miglioretti Diana
Ann Intern Med. 2016 Feb 16;164(4):226-35. doi: 10.7326/M15-0971. Epub 2016 Jan 12.
Women screened with digital mammography may receive false-positive and false-negative results and subsequent imaging and biopsies. How these outcomes vary by age, time since the last screening, and individual risk factors is unclear.
To determine factors associated with false-positive and false-negative digital mammography results, additional imaging, and biopsies among a general population of women screened for breast cancer.
Analysis of registry data.
Participating facilities at 5 U.S. Breast Cancer Surveillance Consortium breast imaging registries with linkages to pathology databases and tumor registries.
405,191 women aged 40 to 89 years screened with digital mammography between 2003 and 2011. A total of 2963 were diagnosed with invasive cancer or ductal carcinoma in situ within 12 months of screening.
Rates of false-positive and false-negative results and recommendations for additional imaging and biopsies from a single screening round; comparisons by age, time since the last screening, and risk factors.
Rates of false-positive results (121.2 per 1000 women [95% CI, 105.6 to 138.7]) and recommendations for additional imaging (124.9 per 1000 women [CI, 109.3 to 142.3]) were highest among women aged 40 to 49 years and decreased with increasing age. Rates of false-negative results (1.0 to 1.5 per 1000 women) and recommendations for biopsy (15.6 to 17.5 per 1000 women) did not differ greatly by age. Results did not differ by time since the last screening. False-positive rates were higher for women with risk factors, particularly family history of breast cancer; previous benign breast biopsy result; high breast density; and, for younger women, low body mass index.
Confounding by variation in patient-level characteristics and outcomes across registries and regions may have been present. Some factors, such as numbers of first- and second-degree relatives with breast cancer and diagnoses associated with previous benign biopsy results, were not examined.
False-positive mammography results and additional imaging are common, particularly for younger women and those with risk factors, whereas biopsies occur less often. Rates of false-negative results are low.
Agency for Healthcare Research and Quality and National Cancer Institute.
接受数字化乳腺钼靶筛查的女性可能会收到假阳性和假阴性结果,以及后续的影像学检查和活检。目前尚不清楚这些结果如何随年龄、上次筛查后的时间以及个体风险因素而变化。
确定在接受乳腺癌筛查的普通女性人群中,与数字化乳腺钼靶检查的假阳性和假阴性结果、额外的影像学检查以及活检相关的因素。
登记数据的分析。
美国乳腺癌监测联盟的5个乳腺影像登记处的参与机构,这些机构与病理数据库和肿瘤登记处有联系。
2003年至2011年期间接受数字化乳腺钼靶筛查的405191名年龄在40至89岁之间的女性。共有2963名女性在筛查后的12个月内被诊断为浸润性癌或原位导管癌。
单次筛查轮次的假阳性和假阴性结果发生率以及额外影像学检查和活检的建议;按年龄、上次筛查后的时间以及风险因素进行比较。
假阳性结果发生率(每1000名女性中有121.2例[95%CI,105.6至138.7])和额外影像学检查建议(每1000名女性中有124.9例[CI,109.3至142.3])在40至49岁的女性中最高,并随着年龄的增长而降低。假阴性结果发生率(每1000名女性中有1.0至1.5例)和活检建议(每1000名女性中有15.6至17.5例)在不同年龄组之间差异不大。结果在上次筛查后的时间方面没有差异。有风险因素的女性假阳性率更高,尤其是有乳腺癌家族史、既往良性乳腺活检结果、乳腺密度高,以及对于年轻女性来说,体重指数低。
各登记处和地区患者水平特征及结果的差异可能存在混杂因素。一些因素,如患乳腺癌的一级和二级亲属数量以及与既往良性活检结果相关的诊断,未进行检查。
乳腺钼靶检查的假阳性结果和额外的影像学检查很常见,尤其是对于年轻女性和有风险因素的女性,而活检则较少发生。假阴性结果发生率较低。
医疗保健研究与质量局和国家癌症研究所。